title: Direct activation of human dendritic cells by particle-bound but not soluble MHC class II ligand.
abstract: Dendritic cells (DCs) are key activators of cellular immune responses through their capacity to induce naïve T cells and sustained effector T cell responses. This capacity is a function of their superior efficiency of antigen presentation via MHC class I and class II molecules, and the expression of co-stimulatory cell surface molecules and cytokines. Maturation of DCs is induced by microbial factors via pattern recognition receptors such as Toll-like receptors, pro-inflammatory cytokines or cognate interaction with CD4(+) T cells. Here we show that, unexpectedly, the PanDR helper T cell epitope PADRE, a generic T helper cell antigen presented by a large fraction of HLA-DR alleles, when delivered in particle-bound form induced maturation of human DCs. The DCs that received the particle-bound PADRE displayed all features of fully mature DCs, such as high expression of the co-stimulatory molecules CD80, CD86, CD83, the MHC-II molecule HLA-DR, secretion of high levels of the biologically active IL-12 (IL-12p70) and induction of vigorous proliferation of naïve CD4(+) T cells. Furthermore, the maturation of DCs induced by particle-bound PADRE was shown to involve sphingosine kinase, calcium signaling from internal sources and downstream signaling through the MAP kinase and the p72syk pathways, and finally activation of the transcription factor NF-κB. Based on our findings, we propose that particle-bound PADRE may be used as a DC activator in DC-based vaccines.
authors: Charité-Universitätsmedizin Berlin, Department of Dermatology, Venerology and Allergology, Berlin, Germany.
authors: Renato B
authors: RB
authors: Baleeiro
authors: Karl-Heinz
authors: KH
authors: Wiesmüller
authors: Lars
authors: L
authors: Dähne
authors: Jürgen
authors: J
authors: Lademann
authors: José A
authors: JA
authors: Barbuto
authors: Peter
authors: P
authors: Walden
mesh_terms: D000595:Amino Acid Sequence; D020013:Calcium Signaling / Q000187:drug effects; D002147:Calmodulin / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D003713:Dendritic Cells / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D042541:Intracellular Space / Q000187:drug effects / Q000378:metabolism; D017780:Malaria Vaccines / Q000737:chemistry* / Q000494:pharmacology*; D010641:Phenotype; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000378:metabolism; D012995:Solubility; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D000099157:Sphingosine Kinase
chemical_list: D002147:Calmodulin; D017780:Malaria Vaccines; D017853:Phosphotransferases (Alcohol Group Acceptor); D000099157:Sphingosine Kinase; C401223:PADRE 45
references: J Leukoc Biol. 2005 Dec;78(6):1397-407
references: 16204647
references: Clin Diagn Lab Immunol. 2004 Jan;11(1):77-82
references: 14715548
references: J Immunother. 2007 Oct;30(7):762-72
references: 17893568
references: Nat Rev Immunol. 2011 Jun;11(6):403-15
references: 21546914
references: Blood. 2000 Aug 1;96(3):1039-46
references: 10910920
references: FEBS Lett. 2003 Feb 11;536(1-3):193-7
references: 12586362
references: Mol Cell Biol. 2011 Nov;31(22):4550-62
references: 21930792
references: Cancer Res. 2006 Jun 1;66(11):5910-8
references: 16740731
references: J Immunol. 2002 Feb 15;168(4):1704-9
references: 11823500
references: Mol Biol Rep. 2012 Mar;39(3):3179-84
references: 21701827
references: J Immunol. 1993 Nov 15;151(10):5115-22
references: 8228213
references: J Exp Med. 2001 Jan 1;193(1):51-60
references: 11136820
references: Nat Immunol. 2000 Aug;1(2):156-62
references: 11248809
references: Nat Neurosci. 2003 Oct;6(10):1072-8
references: 12947408
references: Eur J Immunol. 1999 May;29(5):1617-25
references: 10359116
references: Blood. 2003 Sep 15;102(6):2130-7
references: 12775570
references: J Immunol Methods. 2000 Sep 21;243(1-2):147-54
references: 10986412
references: Proc Natl Acad Sci U S A. 1978 Oct;75(10):5132-6
references: 154105
references: Immunology. 1995 Aug;85(4):611-20
references: 7558157
references: J Immunol. 1992 Jul 15;149(2):735-42
references: 1378080
references: Immunity. 1994 Dec;1(9):751-61
references: 7895164
references: J Immunother. 2000 Mar-Apr;23(2):255-66
references: 10746552
references: Immunol Rev. 2000 Oct;177:134-40
references: 11138771
references: Immunol Res. 2007;39(1-3):115-27
references: 17917060
references: Adv Exp Med Biol. 1995;378:43-52
references: 8526111
references: Crit Rev Immunol. 2003;23(1-2):83-107
references: 12906261
references: Science. 2001 Feb 23;291(5508):1537-40
references: 11222857
references: Annu Rev Immunol. 2006;24:519-40
references: 16551258
references: Angew Chem Int Ed Engl. 2004 Jul 19;43(29):3762-83
references: 15258935
references: Blood. 2002 Nov 1;100(9):3392-9
references: 12384442
references: FEBS Lett. 2004 Aug 13;572(1-3):307-13
references: 15304367
references: Anticancer Res. 2010 Dec;30(12):5091-7
references: 21187495
references: Am J Physiol Cell Physiol. 2011 Jun;300(6):C1205-14
references: 21451105
references: Biochem J. 1995 May 15;308 ( Pt 1):347-52
references: 7538757
references: Neoplasma. 2010;57(5):455-64
references: 20568900
references: Curr Opin Immunol. 2004 Feb;16(1):108-13
references: 14734118
references: Vaccine. 2004 Jun 23;22(19):2362-7
references: 15193395
references: J Immunol. 2000 Nov 15;165(10):5588-96
references: 11067914
references: Vaccine. 2011 Mar 16;29(13):2400-10
references: 21276440